A survivin double point mutant has potent inhibitory effect on the growth of hepatocellular cancer cells

Cancer Biology and Therapy

Volumn 7, Issue 4, 2008, Pages 547-554

  Zhang, Rui ^a   Wang, Tao ^a   Kai, Nan Li ^a   Wei, Wei Qin ^a   Chen, Rui ^a   Wang, Kai ^a   Lin, Tao Jia ^a   Zhao, Jing ^a   Wei, Hong Wen ^a   Yan, Ling Meng ^a   Li, Bo Yao ^a   An, Gang Yang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Adenovirus; Apoptosis; Dominant negative; Gene therapy; Hepatocellular cancer cells; Survivin; Ubiqutin

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; MUTANT PROTEIN; PROTEASOME; PROTEASOME INHIBITOR; SURVIVIN; UBIQUITIN;

ADENOVIRUS; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DNA SEQUENCE; DRUG INHIBITION; GENE TARGETING; GENETIC TRANSFECTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RNA SPLICING; WESTERN BLOTTING;

EID: 45349096313     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.4.5484     Document Type: Article

References (45)

1. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, Survivin, expressed in cancer and lymphoma. Nat Med 1997; 3:917-21.
2. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC. Control of apoptosis and mitotic spindle checkpoint by Survivin. Nature 1998; 396:580-4.
3. Reed JC, Bischoff JR. BIRinging chromosomes through cell division: and survivin' the experience. Cell 2000; 102:545-8.
4. Uren AG, Wong L, Pakusch M, Fowler KJ, Burrows FJ, Vaux DL, Choo KH. Survivin, and the inner centromere protein INCENP show similar cell cycle localization, and gene knockout phenotype. Curr Biol 2000; 10:1319-28.
5. Giodini A, Kallio MJ, Wall NR, Gorbsky GJ, Tognin S, Marchisio PC, Symons M, Altieri DC. Regulation of microtubule stability and mitotic progression by surviving. Cancer Res 2002; 62:2462-7.
6. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC. IAP-family protein Survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998; 58:5315-20.
7. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998; 58:5071-4.
8. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 1999; 341:452-3.
9. Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, Dombret H, Reyes F, Diebold J, Gisselbrecht C, Salles G, Altieri DC, Molina TJ. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000; 96:1921-5.
10. Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J, Fujii Y. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 2001; 95:92-5.
11. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3:46-54.
12. Vile R. Cancer gene therapy - new approaches to tumour cell killing. J Gene Med 2000; 2:141-3.
13. Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognin S, Villa A, Marchisio PC, Altieri DC. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1999; 1:461-6.
14. Chen J, Wu W, Tahir SK, Kroeger PE, Rosenberg SH, Cowsert LM, Bennett F, Krajewski S, Krajewska M, Welsh K, Reed JC, Ng SC. Downregulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. Neoplasia 2000; 2:235-41.
15. Olie RA, Simões Wüst AP, Baumann B, Leech SH, Fabbro D, Stahel RA, Zangemeister Wittke U. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 2000; 60:2805-9.
16. Grossman D, Kim PJ, Schechner JS, Altieri DC. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA 2001; 98:635-40.
17. Mesri M, Wall NR, Li J, Kim RW, Altieri DC. Cancer gene therapy using a survivin mutant adenovirus. J Clin Investig 2001; 108:981-90.
18. Yamamoto T, Manome Y, Nakamura M, Tanigawa N. Downregulation of survivin expression by induction of the effector cell protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer. Eur J Cancer 2002; 38:2316-24.
19. Tu SP, Jiang XH, Lin MC, Cui JT, Yang Y, Lum CT, Zou B, Zhu YB, Jiang SH, Wong WM, Chan AO, Yuen MF, Lam SK, Kung HF, Wong BC. Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res 2003; 63:7724-32.
20. Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, Ito M, Takase K, Moriyama M, Kawano H, Hayashida M, Nakano T, Suzuki A. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 2000; 5:1080-5.
21. Zhu DE, Höti N, Song Z, Jin L, Wu Z, Wu Q, Wu M. Suppression of tumor growth using a recombinant adenoviral vector carrying the dominant-negative mutant gene Survivin-D53A in a nude mice model. Cancer Gene Ther 2006; 13:762-70.
22. O'Connor DS, Grossman D, Plescia J, Li F, Zhang H, Villa A, Tognin S, Marchisio PC, Altieri DC. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of surviving. Proc Natl Acad Sci 2000; 97:13103-7
23. Verdecia MA, Huang H, Dutil E, Kaiser DA, Hunter T, Noel JP. Structure of the human antiapoptotic protein survivin reveals a dimeric arrangement. Nat Struct Biol 2000; 7:602-8.
24. Song Z, Liu S, He H, Hoti N, Wang Y, Feng S, Wu M. A Single Amino Acid Change (Asp 533Ala53) Converts Survivin from Anti-apoptotic to Pro-apoptotic. Mol Biol Cell 2004; 15:1287-96.
25. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95:2509-14.
26. Tu SP, Cui JT, Liston P, Huajiang X, Xu R, Lin MC, Zhu YB, Zou B, Ng SS, Jiang SH, Xia HH, Wong WM, Chan AO, Yuen MF, Lam SK, Kung HF, Wong BC. Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant. Gastroenterology 2005; 2:361-75.
27. Li YM, Wen Y, Zhou BH, Kuo HP, Ding QQ, Hung MC. Enhancement of Bik Antitumor Effect by Bik Mutants. Cancer Res 2003; 63:7630-3.
28. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-ΔEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor surviving with different antiapoptotic properties. Cancer Res 1999; 59:6097-102.
29. Badran A, Yoshida A, Ishikawa K, Goi T, Yamaguchi A, Ueda T, Inuzuka M. Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem Biophys Res Commun 2004; 314:902-7.
30. Caldas H, Honsey LE, Altura RA. Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer 2005; 4:11.
31. Zheng W, Ma X, Wei D, Wang T, Ma Y, Yang S. Molecular cloning and bioinformatics analysis of a novel spliced variant of survivin from human breast cancer cells. DNA Seq 2005; 5:321-8.
32. Caldas H, Jiang Y, Holloway MP, Fangusaro J, Mahotka C, Conway EM, Altura RA. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 2005; 24:1994-2007.
33. Grossman D, Kim PJ, Blanc-Brude OP, Brash DE, Tognin S, Marchisio PC, Altieri DC. Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J Clin Invest 2001; 108:991-9.
34. Conway EM, Pollefeyt S, Steiner-Mosonyi M, Luo W, Devriese A, Lupu F, Bono F, Leducq N, Dol F, Schaeffer P, Collen D, Herbert JM. Deficiency of survivin in transgenic mice exacerbates Fas induced apoptosis via mitochondrial pathways. Gastroenterology 2002; 123:619-31.
35. Zhao J, Tenev T, Martins LM, Downward JL, Lemoine NR. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. Journal of Cell Science 2000; 113:4363-71.
36. Tang ZY. Hepatocellular carcinoma. J Gastroenterol Hepatol 2000; 15:1-7.
37. Suzuki A, Ito T, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y, Akahane K, Nakano T, Miura M, Shiraki K. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene 2000; 10:1346-53.
38. Mah C, Byrne BJ, Flotte TR. Virus-based gene delivery systems. Clin Pharmacokinet 2002; 41:901-11.
39. Li Q, Kay MA, Finegold M, Stratford-Perricaudet LD, Woo SL. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum Gene Ther 1993; 4:403-9.
40. Yang ZR, Wang HF, Zhao J, Peng YY, Wang J, Guinn BA, Huang LQ. Recent developments in the use of adenoviruses and immunotoxins in cancer gene therapy. Cancer Gene Ther 2007; 7:599-615.
41. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 2005; 9:1016-27.
42. Ren XW, Liang M, Meng X, Ye X, Ma H, Zhao Y, Guo J, Cai N, Chen HZ, Ye SL, Hu F. Tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma. Cancer Gene Ther 2006; 13:159-68.
43. Muchmore SW, Chen J, Jakob C, Zakula D, Matayoshi ED, Wu W, Zhang H, Li F, Ng SC, Altieri DC. Crystal structure and mutagenic analysis of the inhibitor-of-apoptosis protein survivin. Mol Cell 2000; 6:173-82.
44. Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 1999; 113:1076-81.
45. Grossman D, McNiff JM, Li F, Altieri DC. Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Lab Invest 1999; 79:1121-6.